Compare M&T Bank Corporation (MTB) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
M&T Bank Corporation vs GeneDx Holdings Corp — how do they compare? M&T Bank Corporation trades at $251.93 (market cap $36.27B), while GeneDx Holdings Corp trades at $81.98 (market cap $2.32B). The key difference: M&T Bank Corporation is far larger — about 15.6× GeneDx Holdings Corp's market cap, and M&T Bank Corporation pays a 2.39% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| MTB | WGS | |
|---|---|---|
Market Cap | $36.27B | $2.32B |
Sector | Financials | Technology |
52-Week High | $254.04 | $167.51 |
52-Week Low | $178.63 | $34.51 |
Dividend Yield | 2.39% | — |
Enterprise Value | — | $2.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
M&T Bank Corporation (MTB) trades at $250.45, up 0.12% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock is supported by strong fundamentals, including a net income margin of 30.85% and a P/E ratio of 13.26, indicating reasonable valuation. Recent Q2 2026 results showed record EPS of $5.35, exceeding expectations, driven by loan growth and net interest income. The consensus price target is $255.92, suggesting modest upside from current levels.
The outlook for MTB remains positive, supported by operational excellence and dividend payments, but risks include macroeconomic sensitivity and competitive pressures in regional banking. Investor sentiment is cautiously optimistic, with analysts largely holding a neutral to buy stance, while institutional ownership trends and cash flow management will be key to sustaining growth.
GeneDx Holdings Corp. (WGS) trades at $77.08, up 10.76% today, showing strong momentum despite negative profitability metrics. The stock exhibits bullish technical signals with support at $72 and resistance at $80. Recent Q2 2026 earnings beat expectations with $0.01 EPS versus -$0.19 estimate, while revenue reached $114.4 million. However, the company faces significant challenges with a -23.4% net income margin and ongoing securities class action litigation.
Investment outlook remains cautiously optimistic given strong analyst support (90.9% buy rating) and $79.25 consensus price target. Key opportunities include growing genomic testing volumes and improved operational efficiency, while risks center on profitability challenges, legal liabilities, and high valuation multiples that may not justify current fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
